Placebo; Vernakalant (oral)
Проводит Advanz Pharma
Страница компанииVernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00526136/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–85 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 735 чел. во всех странах исследования.
- Центров в реестре: 12 в 3 городах. Список — ниже на странице.
- Плановая дата окончания (07.2008) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 14
Критерии включения
- Comprehend and sign a written informed consent form, (per local and national regulations, as applicable)
- Be 18 to 85 years of age
- Women must not be pregnant, be non-nursing and if pre-menopausal, must be using an effective form of birth control from time of screening until 3 months after the last dose of medication. Methods of birth control considered to be effective may include hormonal contraception (the pill), an intrauterine device (IUD), condoms in combination with a spermicidal cream, total abstinence or sterilisation. Men should be advised not to conceive a child and are advised to use an effective form of birth control from admission until 3 months after the last dose of study medication
- Have symptomatic AF that has been sustained for greater than 72 hours and less than 6 months duration and is clinically indicated for cardioversion;
- Have adequate anticoagulant therapy for cardioversion in accordance with standard of practice as recommended by ACC/AHA/ESC guidelines (Fuster V. et al, 2006);
- Be haemodynamically stable (100 mmHg < systolic blood pressure < 190 mmHg) at screening and on Day 1 before dosing (while taking rate control drugs, if required). After resting supine for 3 minutes, blood pressures should be measured 3 times in 5 minutes with at least 1 minute between assessments;
- Have a body weight between 45 and 113 kg (99 and 250 lbs).
Критерии невключения
- Have known prolonged QT syndrome or QTcB interval of >0.500 sec as measured at screening on a 12 lead ECG; familial long QT syndrome; previous Torsades de Pointes; ventricular fibrillation; or sustained ventricular tachycardia (VT).
- Have a QRS >0.140 sec;
- Documented previous episodes of second or third-degree atrioventricular block;
- Have clinically significant persistent bradycardia with ventricular rate below 50 beats/min, sick-sinus syndrome or pacemaker;
- Have clinically significant moderate or severe aortic valvular stenosis (gradient >25 mmHg), hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis;
- Have Class III or Class IV congestive heart failure at screening or admission, or have been hospitalized for heart failure in the previous 6 months;
- Have a myocardial infarction (MI), cardiac surgery, angioplasty, unstable angina or acute coronary syndrome within 30 days prior to entry into the study; h) Have serious pulmonary, hepatic, metabolic, renal (serum creatinine > 2.0 mg/dl), gastrointestinal, central nervous system (CNS) or psychiatric disease, end-stage disease states, or any other disease that could interfere with the conduct or validity of the study or compromise subject safety;
- Have known concurrent temporary secondary causes of AF such as alcohol intoxication, pulmonary embolism, hyperthyroidism, pneumonia, hypoxemia (oxygen saturation < 90% on room air), acute pericarditis, or myocarditis;
- Potassium (K+) <3.5 mmol/L or >5.5 mmol/L or magnesium (Mg2+) below the lower limit of normal (Mg2+< 0.65 mmol/L in subjects 65 years or younger and <0.80 mmol/L in subjects 66 years or older). (Both K+ and Mg2+ should be corrected prior to dosing);
- Have clinical evidence of digoxin toxicity;
- Have received an oral Class I or Class III antiarrhythmic agent (including sotalol) within 3 days of randomisation or oral amiodarone within 4 weeks, or have received intravenous Class I or Class III antiarrhythmic agent or i.v. amiodarone within 24 hours prior to start of dosing;
- Have any other surgical or medical condition that, in the judgment of the clinical Investigator might warrant exclusion or be contraindicated for safety reasons;
- Be concurrently participating in another drug study or have received an investigational drug within 30 days prior to screening;
- Be unable to communicate well with the Investigator and to comply with the requirements of the entire study;
Источник: ClinicalTrials.gov, NCT00526136 · запись обновлена в реестре 18 декабря 2008.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 6
- Time to first documented recurrence of symptomatic sustained AF. — Time to first documented recurrence of symptomatic sustained AF within Day 90 of dosing
- Safety assessments- Vital signs, safety laboratory assays, ECG parameters, physical examinations, and frequency of adverse events — Safety assessments within Day 120 of dosing
Цель исследования
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration \> 72 hours and \< 6 months).
Где проходит
12 центров в 3 городах- City Hospital #29
- FSI EMC of the President of RF, b.o. City Hospital #51
- MedCentre of RF President, Central Clinical Hospital
- Moscow Medical Academy. City Hospital #20
- RMA of Postg. education b.o. Botkin City Clinical Hospital
- Russian Cardiology Research Center
- ГБУЗ города Москвы «Городская клиническая больница № 52 ДЗМ»
- ГБУЗ города Москвы «Госпиталь для ветеранов войн №3 ДЗМ»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00526136 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.